Jiangsu Sihuan Bioengineering Co., Ltd
000518.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.71B
Close$
$0.29
91.1% downside
Current Fair Value
91.1% downsideOvervalued by 91.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.71 Billion |
|---|---|
| Enterprise Value | $3.69 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | 0.28 |
| Outstanding Shares | 1,029,556,221 |
Return
| Return on Equity | -17.11% |
|---|---|
| Return on Assets | -11.49% |
| Return on Invested Capital | -15.83% |
Valuation & Multiples
| P/E Ratio | -70.18 |
|---|---|
| PEG | 20.07 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 13.51 |
| Enterprise Value to EBIT | -64.89 |
| Enterprise Value to Net Income | -70 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jiangsu Sihuan Bioengineering Co., Ltd
232 employees
CEO: Long Chen Jiangsu Sihuan Bioengineering Co., Ltd. is a Chinese pharmaceutical company. Its product portfolio includes anti-cancer biotherapeutics such as Drewson, prescribed for renal cancer, malignant melanoma, and cancerous effusions in the ches...